CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytomX Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.34+0.06 (+2.63%)
Close on Oct 19, 2026
- Market cap
- $512.32M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.86 (−26.88%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CytomX Therapeutics, Inc. saw revenue fall 87.0% to $18.30M over the twelve months to Jun 30, 2026. Operating income fell 302.1% to -$87.15M, moving the operating margin from 30.6% to -476.2%. Free cash flow was -$82.48M.
Revenue
$18.30M
-87.0% vs. a year earlier
Operating income
-$87.15M
-302.1% vs. a year earlier
Free cash flow
-$82.48M
TTM Q2 2026
EPS, diluted
-$0.44
-178.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $512.32M
- P/E ratio
- –
- Price to sales
- 27.99
- Price to book
- 1.70
- Dividend yield
- –
- Free cash flow yield
- -16.10%
Fundamentals
- Revenue
- $18.30M
- Net income
- -$79.65M
- EPS, diluted
- -$0.44
- Free cash flow
- -$82.48M
- Book value per share
- $1.38
- Diluted shares
- 219M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$18.30M-87.0% YoY
Operating income
-$87.15M-302.1% YoY
Net income
-$79.65M-266.0% YoY
EPS, diluted
-$0.44-178.6% YoY
Free cash flow
-$82.48M
Reported periodTrailing twelve months